<h3>领取 TipRanks 高级版 50% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>ADICON Holdings Limited ( (HK:9860) ) 发布了一则公告。</p>
<p>ADICON Holdings Limited 宣布，非执行董事 Feng Janine Junyuan 已辞去董事会及其战略委员会职务，原因是工作安排的变化，公司强调没有分歧，并感谢她的贡献。董事会已任命 Carlyle Asia 的董事总经理 Li Bo，作为新的非执行董事，他是一位在医疗和消费领域拥有丰富市场和运营经验的资深高管，这标志着与控股股东的持续一致，并可能加强董事会层面的战略监督和行业专业知识。</p>
<p>(HK:9860) 股票的最新分析师评级为买入，目标价为 HK$8.60。要查看 ADICON Holdings Limited 股票的完整分析师预测列表，请参见 HK:9860 股票预测页面。</p>
<p><strong>关于 ADICON Holdings Limited 的更多信息</strong></p>
<p>ADICON Holdings Limited 是一家在开曼群岛注册的公司，上市于香港，经营医疗保健行业。其控股股东为 Carlyle Group 的亚洲分支，表明其战略重点与私募股权支持的增长和医疗相关服务及市场的运营提升相一致。</p>
<p><strong>平均交易量：</strong> 3,802,652</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$3.7B</p>
<p>要深入了解 9860 股票，请访问 TipRanks 的概述页面。</p>

艾迪康控股

<p>艾迪康控股有限公司宣布，由于工作安排的变化，非执行董事冯佳妮·君源辞职，且未报告任何分歧。公司已任命凯雷亚洲的董事总经理李波为新的非执行董事，以增强在医疗保健领域的战略监督。最新的分析师评级为艾迪康股票（HK:9860）给予 “买入” 评级，目标价格为 8.60 港元。艾迪康在医疗保健领域运营，并得到凯雷集团亚洲分部的支持，专注于增长和运营提升</p>

<h3>Claim 50% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>领取 TipRanks 高级版 50% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>ADICON Holdings Limited ( (HK:9860) ) has provided an announcement.</p>
<div class="lb-trans"><p>ADICON Holdings Limited ( (HK:9860) ) 发布了一则公告。</p>
</div><p>ADICON Holdings Limited has announced that non-executive director Feng Janine Junyuan has resigned from the board and its strategy committee, citing changes in work arrangements, with the company stressing there is no disagreement and thanking her for her contributions. The board has appointed Carlyle Asia managing director Li Bo, a veteran executive with extensive marketing and operational experience in healthcare and consumer sectors, as a new non-executive director, signaling continued alignment with its controlling shareholder and potentially strengthening strategic oversight and industry expertise at board level.</p>
<div class="lb-trans"><p>ADICON Holdings Limited 宣布，非执行董事 Feng Janine Junyuan 已辞去董事会及其战略委员会职务，原因是工作安排的变化，公司强调没有分歧，并感谢她的贡献。董事会已任命 Carlyle Asia 的董事总经理 Li Bo，作为新的非执行董事，他是一位在医疗和消费领域拥有丰富市场和运营经验的资深高管，这标志着与控股股东的持续一致，并可能加强董事会层面的战略监督和行业专业知识。</p>
</div><p>The most recent analyst rating on (HK:9860) stock is a Buy with a HK$8.60 price target. To see the full list of analyst forecasts on ADICON Holdings Limited stock, see the HK:9860 Stock Forecast page.</p>
<div class="lb-trans"><p>(HK:9860) 股票的最新分析师评级为买入，目标价为 HK$8.60。要查看 ADICON Holdings Limited 股票的完整分析师预测列表，请参见 HK:9860 股票预测页面。</p>
</div><p><strong>More about ADICON Holdings Limited</strong></p>
<div class="lb-trans"><p><strong>关于 ADICON Holdings Limited 的更多信息</strong></p>
</div><p>ADICON Holdings Limited is a Cayman Islands–incorporated company listed in Hong Kong that operates in the healthcare sector. Its controlling shareholder is The Carlyle Group’s Asia arm, indicating a strategic focus aligned with private equity–backed growth and operational enhancement in healthcare-related services and markets.</p>
<div class="lb-trans"><p>ADICON Holdings Limited 是一家在开曼群岛注册的公司，上市于香港，经营医疗保健行业。其控股股东为 Carlyle Group 的亚洲分支，表明其战略重点与私募股权支持的增长和医疗相关服务及市场的运营提升相一致。</p>
</div><p><strong>Average Trading Volume:</strong> 3,802,652</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 3,802,652</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$3.7B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$3.7B</p>
</div><p>For an in-depth examination of 9860 stock, go to TipRanks’ Overview page.</p>
<div class="lb-trans"><p>要深入了解 9860 股票，请访问 TipRanks 的概述页面。</p>
</div>

艾迪康控股重组董事会，凯雷亚洲的一位高管加入担任非执行董事